GlobeNewswire Inc.··Researchandmarkets.ComNeumega Poised for Robust Growth Through 2030 as Oncology Demand Surges
Pfizer's Neumega faces robust growth through 2030 driven by rising cancer diagnoses, chemotherapy intensification, and expanding oncology infrastructure globally.
PFEpersonalized medicineAsia Pacific growth